Simultaneous and Rapid Determination of Six Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Using HPLC-MS/MS.
Journal
International journal of analytical chemistry
ISSN: 1687-8760
Titre abrégé: Int J Anal Chem
Pays: Egypt
ID NLM: 101519424
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
02
2021
accepted:
13
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
To develop a new method for quantitatively analyzing six tyrosine kinase inhibitors (gefitinib, erlotinib, icotinib, afatinib, osimertinib, and crizotinib) used in the treatment of non-small cell lung cancer (NSCLC) by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analytes were detected in the selected reaction monitoring mode on a triple quadrupole mass spectrometer with the positive ionization mode. Carbamazepine was utilized as the internal standard. The pretreatment of the plasma sample was completed based on protein precipitation with acetonitrile, and the analytes were separated on an Agilent Zorbax SB-C18 reversed-phase column (2.1 mm × 100 mm, 3.5 The calibration curves were linear over the range from 5.0 to 1000.0 ng/mL for gefitinib, crizotinib, and osimertinib; from 50.0 to 4000.0 ng/mL for icotinib and erlotinib; and from 5.0 to 400.0 ng/mL for afatinib. Linear correlation coefficients were >0.990 for all regression curves. The intra- and interday accuracy and precision of the method were within ±15.0% and not more than 15.0%, respectively. The mean recovery of all the analytes ranged from 70.18% to 110.76%, the matrix effect was from 88.85% to 127.58%, and stability was within ±15.0%. This newly developed method was sensitive, simple, and robust and could be used in therapeutic drug monitoring of six tyrosine kinase inhibitors in NSCLC patients.
Identifiants
pubmed: 34567122
doi: 10.1155/2021/5524361
pmc: PMC8463214
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5524361Informations de copyright
Copyright © 2021 Yanping Liu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Clin Pharmacokinet. 2014 Apr;53(4):305-25
pubmed: 24566736
J Thorac Dis. 2020 Mar;12(3):639-650
pubmed: 32274129
J Pharm Biomed Anal. 2018 Jan 30;148:65-72
pubmed: 28965046
Jpn J Clin Oncol. 2019 Jul 1;49(7):676-686
pubmed: 31008509
Biomed Chromatogr. 2016 Jul;30(7):1150-1154
pubmed: 26525154
Ther Drug Monit. 2017 Feb;39(1):43-54
pubmed: 27861317
J Pharm Biomed Anal. 2018 Sep 5;158:174-183
pubmed: 29883880
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
PeerJ. 2020 Sep 22;8:e9881
pubmed: 33024629
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:17-22
pubmed: 30366208
Biomolecules. 2019 Oct 30;9(11):
pubmed: 31671561
Invest New Drugs. 2020 Dec;38(6):1687-1695
pubmed: 32436059
J Pharm Biomed Anal. 2018 Feb 20;150:112-120
pubmed: 29220734
Front Pharmacol. 2018 Aug 07;9:849
pubmed: 30131694
Eur J Pharm Sci. 2019 May 15;133:145-159
pubmed: 30946965
J Clin Pharmacol. 2017 Oct;57 Suppl 10:S78-S98
pubmed: 28921641
Clin Pharmacol Ther. 2021 Feb;109(2):394-402
pubmed: 32686074
Cancer Chemother Pharmacol. 2019 May;83(5):849-858
pubmed: 30762084
Clin Pharmacokinet. 2017 Mar;56(3):235-250
pubmed: 27470518
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Future Oncol. 2018 May;14(11):1117-1132
pubmed: 29336166
Sci Rep. 2019 Dec 3;9(1):18202
pubmed: 31796841
Am Soc Clin Oncol Educ Book. 2014;:177-89
pubmed: 24857075